Rexahn Pharmaceuticals has been issued a United States patent, titled "1-(6,7-substituted alkoxyquinoxalinyl aminocarbonyl)-4-(hetero) arylpiperazine derivatives." This new patent covers Rexahn’s quinoxalinyl-piperazine compounds, the process for the preparation of such compounds and their pharmaceutical composition. The patent includes Rexahn’s RX-5902, a first-in-class p68 helicase inhibitor, that is an orally available new chemical entity exhibiting potent antitumor properties in several types of tumors.
- Company Legal & Law Matters
- Pharmaceuticals & Drug Trials